



28 January 2025

To Whom It May Concern

## DIVESTMENT OF TARCEVA® (ERLOTINIB) TO CHEPLAPHARM

Dear Healthcare Professionals,

Kindly be informed that Roche has divested TARCEVA TABLETS 100mg (SIN13185P ) and TARCEVA TABLETS 150mg (SIN13184P) globally to CHEPLAPHARM Schweiz GmbH ('CHEPLAPHARM'), Switzerland. As part of the divestment, marketing authorization of Tarceva® will be transferred to CHEPLAPHARM in Singapore on **7 March 2025**.

Please note that with effect from 7 March 2025, DKSH will no longer be the Marketing distributor for Tarceva. Please find below the key dates relating to orders and delivery:

Activity Description	Cut-Off Date
<b>Last submission of sale orders to Roche</b>	6 March 2025 (before 5pm)
<b>Last Delivery Date</b> (for orders submitted on/before 6 March 2025 )	7-10 March 2025


Healthcare professionals can report adverse events relating to Tarceva® to the Vigilance and Compliance Branch, Health Products Regulation Group, HSA, at Tel: +65 6866 3538 or report online at:

<http://eservice.hsa.gov.sg/adr/adr/adrOnline.do?action=loadOnlineForm>. Alternatively, adverse events or quality complaints relating to Tarceva® should be reported to Zuellig Pharma Pte Ltd after 7 March 2025 via **Tel:** 1800 214 2132 or **Email:** [sgcustomercare@zuelligpharma.com](mailto:sgcustomercare@zuelligpharma.com).

If you have any questions concerning this correspondence and/or Tarceva® please do not hesitate to contact CHEPLAPHARM via Zuellig Pharma Pte Ltd **Tel:** 1800 214 2132 or **Email:** [sgcustomercare@zuelligpharma.com](mailto:sgcustomercare@zuelligpharma.com).

Yours Sincerely,

DocuSigned by:  
  
E922B4A169BA450...  
**Yeoh Ying Ying**  
General Manager

Signed by:  
  
D6FBC7F9CE04446...  
**Noemie Heron**  
Finance Director and Business Insights &  
Operations Chapter Lead